Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2025
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapyAlison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, et al.
Annals of Surgical Oncology|December 29, 2022
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal LiposarcomaMark A Eckardt, Danielle S Graham, Kyle D Klingbeil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabTheodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Surgery|October 10, 2025
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patientsMark A Eckardt, Nicholas M Siena, Amy R Copeland, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Cell|January 17, 2018
LXR/ApoE Activation Restricts Innate Immune Suppression in CancerMasoud F Tavazoie, Ilana Pollack, Raissa Tanqueco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Pageof 20